Neurology
-
Randomized Controlled Trial Multicenter Study
Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study.
To evaluate the efficacy, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS; gammaCore; electroCore, LLC, Basking Ridge, NJ) for the acute treatment of migraine in a multicenter, double-blind, randomized, sham-controlled trial. ⋯ This study provides Class I evidence that for patients with an episodic migraine, nVNS significantly increases the probability of having mild pain or being pain-free 2 hours poststimulation (absolute difference 13.2%).
-
Randomized Controlled Trial Multicenter Study
Neurologic outcomes in pediatric cardiac arrest survivors enrolled in the THAPCA trials.
To implement a standardized approach to characterize neurologic outcomes among 12-month survivors in the Therapeutic Hypothermia after Pediatric Cardiac Arrest (THAPCA) trials. ⋯ The PRCA provides a robust method for depicting neurologic outcomes after acute encephalopathy caused by CA in children. It provides a global semiquantitative rating of neurologic impairment and domain-specific impairment. The strong correlation with well-established neurobehavioral outcome measures supports its validity over a broad age range and wide spectrum of outcomes.
-
Randomized Controlled Trial Multicenter Study
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
To evaluate the safety and efficacy of crenezumab in patients with mild to moderate Alzheimer disease (AD). ⋯ This study provides Class II evidence that, for people with AD, crenezumab does not significantly improve cognition or function at 18 months. The study is rated Class II because <80% of enrolled patients completed the study.
-
Randomized Controlled Trial Multicenter Study
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS). ⋯ This study provides Class I evidence that for patients with RMS, ofatumumab decreases the number of new MRI gadolinium-enhancing lesions 12 weeks after treatment initiation.
-
Multicenter Study
A multicenter examination and strategic revisions of the Yale Global Tic Severity Scale.
To examine the internal consistency and distribution of the Yale Global Tic Severity Scale (YGTSS) scores to inform modification of the measure. ⋯ The YGTSS exhibits good internal consistency across children and adults. The parallel findings across Motor and Phonic Frequency, Complexity, and Interference dimensions prompted minor revisions to the anchor point description to promote use of the full range of scores in each dimension. Specific minor revisions to the YGTSS Phonic Tic Symptom Checklist were also proposed.